Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways

Biochemical Pharmacology

Volumn 54, Issue 7, 1997, Pages 801-808

  Lenhard, James M ^a   Kliewer, Steven A ^a   Paulik, Mark A ^a   Plunket, Kelli D ^a   Lehmann, Jurgen M ^a   Weiel, James E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Diabetes; Insulin; Metabolism; Metformin; PPAR ; Troglitazone

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; LACTIC ACID; METFORMIN; PEROXISOME PROLIFERATOR; TROGLITAZONE;

ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CYTOCHEMISTRY; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT; CHROMANS; GLUCOSE; HYPOGLYCEMIC AGENTS; LACTIC ACID; LIPID METABOLISM; METFORMIN; MICE; MICE, INBRED C3H; MITOCHONDRIA; PALMITOYL COENZYME A; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0030773456     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00229-3     Document Type: Article

References (36)

1. Defronzo RA, Bonadonna RC and Ferrannini E, Pathogenesis of NIDDM. Diabetes Care 15: 317-368, 1992.
2. Kumar S, Boulton AJM, Back-Nielsen H, Berthezene F, Muggeo M, Persson B, Spinas GA, Donoghue S, Lettis S and Stewart-Long P, Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia 39: 701-709, 1996.
3. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S and Shigeta Y, A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11: 147-153, 1991.
4. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270: 12953-12956, 1995.
5. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83: 813-819, 1995.
6. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83: 803-812, 1995.
7. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM and Kliewer SA, Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410, 1997.
8. Castelein H, Gulick T, Declercq PE, Mannaerts GP, Moore DD and Baes MI, The peroxisome proliferator activated receptor regulates malic enzyme gene expression. J Biol Chem 269: 26754-26758, 1994.
9. Tontonoz P, Hu E, Devine J, Beale EG and Spiegelman BM, PPARγ2 regulates adipose expression of the phosphoenol-pyruvate carboxykinase gene. Mol Cell Biol 15: 351-357, 1995.
10. Hiragun A, Sato M and Mitsui H, Preadipocyte differentiation in vitro: Identification of a highly active adipogenic agent. J Cell Physiol 134: 124-130, 1988.
11. Kletzien RF, Clarke SD and Ulrich RG, Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393-398, 1992.
12. Tontonoz P, Hu E and Spiegelman B, Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79: 1147-1156, 1994.
13. Bailey CJ, Biguanides and NIDDM. Diabetes Care 15: 755-772, 1992.
14. Wiernsperger N and Rapin JR, Metformin-insulin interactions: From organ to cell. Diabetes Metab Rev 11: S3-S12, 1995.
15. Cigolini M, Bosello O, Zancanaro C, Orlandi PG, Fezzi O and Smith U, Influence of metformin on metabolic effect of insulin in human adipose tissue in vitro. Diabete Metab 10: 311-315, 1984.
16. Matthaei S, Hamann A, Klein H, Benecke H, Kreymann G, Flier J and Greten H, Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to the plasma membrane in rat adipocytes. Diabetes 40: 850-856, 1991.
17. Kozka IJ and Holman GD, Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes 42: 1159-1165, 1993.
18. Bailey CJ and Puah JA, Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab 12: 212-218, 1986.
19. Wilcock C and Bailey CJ, Sites of metformin-stimulated glucose metabolism. Biochem Pharmacol 39: 1831-1834, 1990.
20. Abdel-aleem S and Frangakis C, Stimulation of fatty acid oxidation by phosphodiesterase III inhibitors in rat myocytes. J Cardiovasc Pharmacol 18: 293-297, 1991.
21. 14C]fatty acid oxidation. Biochem Med Metab Biol 35: 248-259, 1986.
22. Lazarow PB, Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol 72: 315-319, 1981.
23. Haugland RP, Handbook of Fluorescent Probes and Research Chemicals (Ed. Spence MTZ), 6th Edn, pp. 266-273. Molecular Probes, Inc., Eugene, OR 1996.
24. Lenhard JM, Hamacher L, Paulik M, Beck K, Kliewer SA, Lehmann JM, Cobb J, Henke B, Willson T, Parks D and Blanchard S, Analysis of thiazolidinedione, biguanide, and retinoid effects on adipogenesis and the nuclear receptors PPARγ and RXR. Diabetologia 39[Suppl 1]: 234, 1996.
25. 3-Adrenoreceptor: An update. Eur J Endocrinol 132: 377-385, 1995.
26. Riccio A, Del Prato S, Vigili de Kreutzenberg S and Tiengo A, Glucose and lipid metabolism in non-insulin dependent diabetes. Effect of metformin. Diabete Metab 17: 180-184, 1991.
27. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I and Horikoshi H, Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558, 1988.
28. Fedele D, Tiengo A, Nosadini R, Marchiori E, Briani G, Garotti MC and Muggeo M, Hypolipodemic effects of metformin in hyperprebetalipoproteinaemia. Diabete Metab 2: 127-133, 1976.
29. Hermann LS, Metformin. A review of its pharmacological properties and therapeutic use. Diabete Metab 5: 233-245, 1979.
30. Paulik MA and Lenhard JM, Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase and increasing mitochondrial mass in C3H10T1/2 cells. Cell Tissue Res, in press.
31. Tai TAC, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC and Graves RA, Activation of the nuclear receptor peroxisome proliferator-activated receptor γ promotes brown adipocytre differentiation. J Biol Chem 271: 29909-29914, 1996.
32. Bailey CJ, Wilcock C and Day C, Effect of metformin on glucose metabolism in the splachnic bed. Br J Pharmacol 105: 1009-1013, 1992.
33. Fulgencio J-P, Kohl C, Girard J and Pégorier J-P, Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes 45: 1556-1562, 1996.
34. El-Kebbi IM, Roser S and Pollet RJ, Regulation of glucose-transport pioglitazone in cultured muscle cells. Metabolism 43: 953-957, 1994.
35. Hiroyoshi H, Yoshioka T, Kawasaki T, Nakamura K, Matsunuma N, Yamaguchi Y and Sasahara K, Troglitazone (CS-045), a new antidiabetic drug. Annu Rep Sankyo Res Lab 46: 1-57, 1994.
36. Stern J, Pharmacology and mode of action of hypoglycaemic guanidine derivatives. In: Oral Hypoglycaemic Agents (Ed. Campbell GD), pp. 193-245. Academic Press, London, 1969.